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Purpose or Objective: To determine the optimum 
combination of treatment parameters between pitch, field 
width (FW) and number of irradiation fields for left-sided 
whole breast irradiation using static tomotherapy (« 
TomoDirect™ »). 
 
Material and Methods: 15 patients already treated with 
conformal radiotherapy for left-sided breast cancer without 
lymph nodes were selected for this study. A total of 180 
TomoDirect™ plans were created by varying the field width 
(2.5 and 5 cm), the pitch (0.125, 0.250 and 0.5 
cm/projection) and the number of irradiation fields (2 and 
4). Modulation factor (MF) was set to 2 and dynamic jaws 
were not available. Prescribed dose was 50 Gy in 25 fractions 
without tumoral boost. Constraints were applied on the 
planning treatment volume (PTV) to ensure that 98% of the 
PTV receives at least 95% of the prescribed dose and 2% 
receives at most 107%. Treatment plans were assessed 
collecting Homogeneity Index (HI) for the PTV, mean doses 
(heart, ipsilateral and contralateral lung) and maximum dose 
(contralateral breast) for the organs-at-risk (OAR), integral 
dose to the patient and beam-on time. To assess whether 
breast size has an impact on dose homogeneity to the PTV, 
we separated the 15 patients into 2 cohorts of small (volume 
< 600 cc) and large (> 600 cc) PTV and compared HI. 
 
Results: Modifying the pitch has no effect on either plan 
quality (PTV and OAR) or on irradiation time. Increasing the 
number of beams from 2 to 4 has no significant effect on OAR 
doses, but improves the HI of the PTV (0.068 ± 0.010 for 2 
fields and 0.061 ± 0.011 for 4 fields) without altering 
significantly irradiation time (4.48 ± 1.27 min for 2 fields and 
4.82 ± 1.30 min for 4 fields). Comparison of HI between small 
and large PTV shows that PTV volume has no significant 
effect on HI. Also, HI improvement does not depend on PTV 
volume, meaning that switching from 2 to 4 fields of 
irradiation is always beneficial (~ 10% better). Beam-on times 
are lowered using a FW = 5 cm (3.49 ± 0.37 min) rather than 
a FW = 2.5 cm (5.81 ± 0.70 min). On the other hand, the FW 
has no significant impact on OAR or PTV doses, except for the 
integral dose that is respectively 95.72 ± 35.22 Gy.L for a FW 
= 2.5 cm and 105.3 ± 38.1 Gy.L for a FW = 5 cm. Keep in mind 
that these results are obtained with a fixed MF = 2. 
 
Conclusion: While setting the modulation factor to 2, pitch 
value seems to have no impact on planning quality or on 
irradiation time. A field width of 5 cm with 4 fields of 
irradiation is a good combination of treatment parameters for 
treating left-sided whole breast cancer with TomoDirect™ if 
dynamic jaws are available. If not the case, a field width of 
2.5 cm is more suitable so that the integral dose to patients 
is lowered and radiation-induced secondary malignancies are 
minimized. This study will be completed by delivery QA to 
confirm that delivered doses match calculated ones. 
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Purpose or Objective: From the biological aspects of 
prostate cancer, hypofractionated external beam radiation 
therapy (EBRT) or high-dose-rate brachytherapy (HDR-BT) has 
been considered as a treatment choice for prostate cancer to 
improve local control, especially for high risk disease because 
the alpha-beta ratio for prostate cancer was around 1.5-3 Gy, 
lower than that for other cancers. Therefore, the purpose of 
this study is to evaluate outcomes and toxicities of 
hypofractionated EBRT combined with HDR-BT for high risk 
prostate cancer. 
 
Material and Methods: We retrospectively analyzed 111 
patients with localized prostate cancer (T1-3N0M0) that was 
defined as high risk disease based on the D’Amico 
classification, which includes cases of stage T2c to T3b or 
those with Gleason score of 8 to 10 or prostate-specific 
antigen (PSA) greater than 20 ng/mL. All patients had 
received hypofractionated EBRT (45 Gy in 15 fractions every 
other weekday for 5 weeks) followed by HDR-BT (18 Gy in 2 
fractions for one day) between June 1, 2007 and September 
30, 2011 at our institution. Androgen deprivation therapy 
(ADT) consisted of 3 to 6 months’ neoadjuvant ADT before 
and during radiation therapy and 6 months’ adjuvant ADT 
after radiation therapy. Biochemical failure was defined as 
PSA nadir plus 2.0 ng/mL according to the Phoenix definition. 
We scored genitourinary (GU) and gastrointestinal (GI) 
toxicities based on the Common Terminology Criteria for 
Adverse Events Version 4, and calculated the rates of overall 
and biochemical-free survival using the Kaplan-Meier method, 
timed from the completion of the HDR-BT to death or earliest 
failure. Statistical analyses were performed by using SPSS 
software. 
 
Results: During follow-up (median, 62 months; range, 4 to 99 
months), 24 of 111 patients (21.6%) experienced biochemical 
failure (median, 41.5 months; range, 12.7 to 72.1 months). 
The rates of 5-year overall survival and biochemical-free 
survival were 99.0% and 80.3%, respectively. At the time of 
analysis, only 1 patient had died of other disease. Among 24 
patients with biochemical failure, 1 pateint developed bone 
metastasis, 2 patients developed pelvic lymph node 
recurrence, and 21 patients diagnosed with PSA failure alone. 
GU acute toxicity was Grade 1 or less in 99 patients and 
Grade 2 in 12 patients. GU late toxicity was Grade 1 or less in 
108 patients and Grade 2 in 3 patients. GI toxicity including 
rectal bleeding was Grade 1 or less in 109 patients and Grade 
2 in 2 patients. 
 
Conclusion: The results of this study suggest that 
hypofractionated EBRT combined with HDR-BT can be 
feasible for high risk prostate cancer, although follow-up 
period is not long enough to get a definitive conclusion. 
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Purpose or Objective: With improvements in survival for 
good performance status patients with glioblastoma, some 
patients will survive to develop significant neurocognitive 
dysfunction. This retrospective planning study quantifies 
hippocampal radiation doses in twenty-five patients with 
glioblastoma receiving radical chemo-radiation therapy, and 
evaluates the potential for dose reduction using helical IMRT 
(Tomotherapy).  
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Material and Methods: We identified twenty-five 
glioblastoma patients treated with helical IMRT 
(Tomotherapy) with concurrent and adjuvant temozolamide 
between October 2011 and December 2013 from our 
radiotherapy electronic database and conducted a 
retrospective analysis. Hippocampi were contoured in CT and 
MRI co-registered image data sets used for clinical 
radiotherapy planning and hippocampus planning risk volumes 
(PRV) were created by adding five-millimetre isotropic 
margin which were checked by a neuro radiologist. Clinical 
treatment dosimetry plans were overlaid to obtain dose 
statistics. Four selected patients were planned for 
hippocampus avoidance radiotherapy without compromising 
tumour PTV coverage using currently established 
hippocampus dose volume histogram (DVH) constraints.  
 
Results: Mean hippocampus PRV maximum, minimum and 
mean radiation doses were 54.7, 24.15 and 38.62 Gy 
respectively. Hippocampus PRV V7.3, V14.9 and V20 were 
99.95%, 98.41% and 95.72% and hippocampus V3 was 100%. In 
seventeen patients ipsilateral hippocampus was within PTVs 
and in seven patients both hippocampi were outside PTVs 
with only minimal overlapping volumes but DVH based dose 
constraints were not achieved.  
 
 
With hippocampus avoidance planning (HA), in four patients 
hippocampus PRV minimum doses and in 3 patients mean 
hippocampus PRV doses were reduced and significant 
reductions in DVH based dose constraints were achieved in 3 
patients when compared to clinical treatment plans (table).  
 
Conclusion: Our analysis showed hippocampus PRVs received 
significant radiation doses and currently established 
hippocampus DVH based dose constraints were not achieved 
during cranial radiotherapy for glioblastoma using helical 
IMRT without hippocampus avoidance planning. Our planning 
study demonstrated significant dose reductions were possible 
with hippocampus avoidance radiotherapy planning in 
selected patients. More clinically correlated DVH objectives 
for hippocampus are required for better optimisation for 
hippocampus avoidance cranial radiotherapy in glioblastoma 
for this to be considered for all patients.  
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Purpose or Objective: To provide a comparison of 6 
different treatment planning strategies, adopted for breast 
conserving-adjuvant RT, on the dose to the PTV and OARs. 
 
Material and Methods: 22 patients CT data sets were 
retrospectively used for planning comparison. Patients were 
split in two groups of 6 left- and 5 right-sided cases (G1 and 
G2) according to the different dose prescription (50 Gy in 25 
fractions and 42.4 Gy in 16 fractions for G1 and G2, 
respectively). The 6 techniques involved were: Field in Field 
(FiF), 2 Fields static-IMRT (sIMRT-2ff), 4 Fields static-IMRT 
(sIMRT-4FF), VMAT, Helical Tomotherapy (HT) and Tomo 
Direct (TD). Dose limits applied to PTV and OARs were taken 
from the RTOG protocol n.1005. Treatments plans were 
optimized to reduce dose to Ipsilateral Lung (IL), 
Contralateral Breast (CB) and, for left-sided cases, Heart (H) 
while maintaining an acceptable PTV coverage and 
homogeneity. The Wilcoxon matched-paired signed-rank test 
was used to compare the results. The threshold for statistical 
significance was p≤0.05.  
 
Results: The highest mean value V95%=98.8%/99.2% (G1/G2) 
was observed for TD and it was statistically significant with 
respect to all others techniques except to VMAT. Similar 
results were obtained for D98%. The lowest mean 
V105%=0.2%/0.1% (G1/G2) was found for HT resulting 
statistically significant if compared to all other techniques 
except FIF/VMAT in G1 /G2, respectively. Mean D2% was also 
found lowest for HT (52.1Gy/43.1Gy in G1/G2) resulting 
statistically significant with respect to all other techniques 
except versus TD in G2. For IL mean V5(Gy), V10(Gy) and 
dose mean were lowest for TD in both groups (20.1%/19.1%, 
14.2%/13% and 5.8%/4.9% in G1/G2, respectively) being 
statistically significant versus all other techniques in G1. The 
lowest values of mean V20(Gy)=7.0%/7.9% were observed for 
HT in both groups. CB dose maximum was found as lowest in 
G1 for TD (290.9cGy) and for FiF in G2 (252,6cGy) both 
resulting statistically significant versus all other techniques 
except for FiF in G1 and TD in G2 confirming a substantial 
equivalence for the two techniques. Minor absolute dose 
differences were observed for H.  
 
Conclusion: 6 different techniques were employed to design 
an optimal plan for conserving breast-adjuvant RT fulfilling 
the dose limit criteria provided by RTOG 1005 protocol. TD 
provided superior target coverage maintaining a level of 
homogeneity similar to HT which achieved the highest value. 
IL dose was minimized with TD while dose to CB was lowest 
using both FiF and TD techniques.  
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Purpose or Objective: Preoperative Radiotherapy (RT) may 
theoretically improve resectability in locally advanced 
pancreatic cancer. However, effective doses of RT are 
limited by the tolerance of surrounding tissues. Stereotactic 
radiotherapy (SRT) with intensity-modulated technique 
(IMRT) based on the use of a Simultaneous Integrated Boost 
may theoretically allow to deliver a low dose to the 
duodenum (site of more common toxicity) and a high dose to 
the vessel invasion (more common reason of unresectability). 
Aim of this study was to perform a planning feasibility 
analysis of a modulated dose prescription within a pancreatic 
tumor treated by SRT. 
 
Material and Methods: 15 patients with a histological 
confirmation of pancreatic head adenocarcinoma with 
vascular involvement were included. The following 
definitions for targets were used: duodenal PTV (PTVd) was 
defined as the GTV overlapping the duodenal planning at risk 
volume (PRV) (from the pylorus to the duodenojejunal 
junction adding 5 mm in craniocaudal direction (CC), 3 mm in 
the other directions); vascular CTV (CTVv) was defined as the 
surface of contact or infiltration between tumor and vessel 
plus 5 mm margin around the vessel (including the whole 
